| abstract |
The present invention provides methods for determining the administration of cells engineered with recombinant receptors, such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). In some embodiments, the method comprises determining a therapeutic range for administration by an estimated probability of risk of toxicity upon administration and an estimated probability of response to said engineered cell. |